Study subjects
bone loss, inflammation, cancer, liver or kidney dysfunction/failure, fracture, allergy, peri-implantitis, CBL loss
BONE LOSS, ACUTE INFECTIONS, INFLAMMATION, CANCER, DIABETES MELLITUS, ALLERGY
The study subjects were recruited among patients in maintenance care program in a private dental clinic, Stavanger, Norway, from December 2019 through November 2020. Eligible subjects were healthy adults, age 20–85 years, who had received one or more dental implants that had been in function for more than 12 months and restored with an adequate prosthetic restoration. The inclusion criterium was diagnosis of peri-implantitis on at least one dental implant based on the definition from the consensus report of workgroup 4 of the 2017 World Workshop [Exclusion criteria were surgical treatment of peri-implantitis within the last 6 months (previous surgical management of peri-implantitis was not an exclusion criterium), inflammation around the implant without evidence of bone loss or with CBL loss < 2 mm, maintenance care therapy within 3 months before initiation of the study, and use of systemic antibiotic within 6 months. Subjects with diabetes mellitus, cancer, HIV/AIDS, acute infections, liver or kidney dysfunction/failure, a history of non-compliant behavior, periapical peri-implantitis, implant fracture, ceramic implants, current pregnancy or breast-feeding, allergy to erythritol, and deficient fixed prosthesis were also excluded [